MRI-guided radiotherapy for prostate cancer: the MOMENTUM study 127 References 1. de Muinck Keizer DM, Kerkmeijer LGW, Willigenburg T, van Lier ALHMW, den Hartogh MD., van der Voort van Zyp JRN, et al. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac. Radiother Oncol 2020;151:88–94. 2. Chin S, Eccles CL, McWilliam A, Chuter R, Walker E, Whitehurst P, et al. Magnetic resonance-guided radiation therapy: A review. J Med Imaging Radiat Oncol 2020;64:163–77. 3. Zachiu C, Denis De Senneville B, Willigenburg T, Voort Van Zyp JRN, De Boer JCJ, Raaymakers BW, et al. Anatomically-adaptive multi-modal image registration for image-guided external-beam radiotherapy. Phys Med Biol 2020;65. 4. Klüter S. Technical design and concept of a 0.35 T MRLinac. Clin Transl Radiat Oncol 2019;18:98–101. 5. Lagendijk JJW, Raaymakers BW, van Vulpen M. The Magnetic Resonance Imaging-Linac System. Semin Radiat Oncol 2014;24:207–9. 6. Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, et al. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results. Int J Radiat Oncol Biol Phys 2019;105:1086–94. 7. Tetar SU, Bruynzeel AME, Oei SS, Senan S, Fraikin T, Slotman BJ, et al. Magnetic Resonance-guided Stereotactic Radiotherapy for Localised Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study. Eur Urol Oncol 2021;4:628–34. 8. de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, et al. Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. Int J Radiat Oncol Biol Phys 2021;111:867–75. 9. de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, et al. The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Front Oncol 2020;10. 10. Identifier: NCT04075305, The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study, August 30, 2019. Clin Bethesda Natl Libr Med (US).https://clinicaltrials.gov/ct2/show/NCT0407530 5 (accessed June 1, 2022). 11. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med 2012;366:2443–54. 12. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: A qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76. 13. van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008;44:2418–24. 14. Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM, et al. Adaptive radiotherapy: The Elekta Unity MR-linac concept. Clin Transl Radiat Oncol 2019;18:54–9. 15. Willigenburg T, de Muinck Keizer DM, Peters M, Claes A, Lagendijk JJW, de Boer HCJ, et al. Evaluation of daily online contour adaptation by radiation therapists for prostate cancer treatment on an MRI-guided linear accelerator. Clin Transl Radiat Oncol 2021. 16. Fritz CO, Morris PE, Richler JJ. Effect size estimates: Current use, calculations, and interpretation. J Exp Psychol Gen 2012. 17. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, et al. Stereotactic Body Radiation Therapy for Localised Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys 2019;104:778–89. 18. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20:1531–43. 19. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. J Am Med Assoc 2005;294:238–44. 20. Loi M, Wortel RC, Francolini G, Incrocci L. Sexual Function in Patients Treated With Stereotactic Radiotherapy For Prostate Cancer: A Systematic Review of the Current Evidence. J Sex Med 2019;16:1409–20. 6
RkJQdWJsaXNoZXIy MTk4NDMw